Viruses are known to be highly susceptible to mutations, often resulting in the emergence of variant strains. While some will disappear, others will persist and challenge our global healthcare system, just as we saw with the COVID-19 pandemic.
Join us in a conversation with Scott Dessain (OCMS) and Marko Jovic (Nicoya), who will discuss the application of novel mAb screening technology and surface plasmon resonance (SPR) for rapid discovery and characterization of variant-specific antibodies, and will delve into the future of immunodiagnostics.
- Challenges of emerging viral variants
- New strategies for viral detection
- Accelerating antibody discovery with rapid screening and characterization
- Emerging technologies for mAb engineering
Nicoya's Benchtop SPR Instruments
Scott Dessain, MD, PhD
Founder, CSO at OCMS
Marko Jovic, PhD
Training & Development
Manager at Nicoya